RCT was conducted to evaluate efficacy and safety of drug simvastatin compared to placebo in reducing mortality and morbidity in patients with coronary heart disease. Subjects were followed up on average 5.4 years. Over the duration of the follow-up, 63 subjects died due to heart attack among 2,223 subjects in the placebo group compared to 30 deaths among 2,221 patients in the simvastatin drug group.

Question #1. What is the Relative Risk or death from the heart attack in the simvastatin group?

NOTE: Only provide the number in the answer box. Provide you answer with 2 digits after decimal point (two decimal places)!